Wikipedia -WSS

Wikipedia

author：fashion 2025-08-23 05:02:25 - browse：7464

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： What health policies could hitch a ride on a spending bill?

WSS

Stem cell treatment guidelines are released by FDA

What American doctors can learn from their Israeli counterparts

NIH chief: government has fallen behind pharma on clinical trials

After decades in use, heart stents finally beat placebo

How state and local governments are sidelining science

Stem cell treatment guidelines are released by FDA

leisure time

Wikipedia

hotspot

Medicare details structure of new drug price negotiation program

Amazon on where the company's health care bets are headed next

At least 13 dead in Texas as scorching temps continue

Why Novartis is changing the name of its research labs

23andMe had bad news about my health. I wish a person had delivered it

What drug price negotiations mean for Medicare Part D

Drug repurposing or repositioning? The language matters

What health policies could hitch a ride on a spending bill?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medicaid rebukes states for mistakenly disenrolling children

hotspot

Medicare’s new pay boost for primary care is angering specialists

The 10 drugs up first for Medicare price negotiation

Listen: Biogen's potential pivot, & Illumina's next chapter

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

NIH nominee Bertagnolli will get October confirmation hearing

Stem cell treatment guidelines are released by FDA

leisure time

hotspot

focus

knowledge